Targeted therapy for breast cancer in older patients.

Auteurs : Pondé N, Wildiers H, Awada A, de Azambuja E, Deliens C, Dal Lago L
Année : 2020
Journal : J Geriatr Oncol
Volume : 11
Pages : 380-388

Feasibility and clinical impact of routine molecular testing of gastrointestinal cancers at a tertiary centre with a multi-gene, tumor-agnostic, next generation sequencing panel.

Auteurs : Bregni G, Sticca T, Camera S, Akin Telli T, Craciun L, Trevisi E, Pretta A, Kehagias P, Leduc S, Senti C, Deleporte A, Vandeputte C, Saad ED, Kerger J, Gil T, Piccart-Gebhart M, Awada A, Demetter P, Larsimont D, Hendlisz A, Aftimos P, Sclafani F
Année : 2020
Journal : Acta oncol (Stockholm)
Volume : 59
Pages : 1438-1446

Metronomic chemotherapy for patients with metastatic breast cancer: Review of effectiveness and potential use during pandemics.

Auteurs : Fares JE, El Tomb P, Khalil LE, Atwani RW, Moukadem HA, Awada A, El Saghir NS
Année : 2020
Journal : Cancer Treat Rev
Volume : 89
Pages : 102066

Targeting molecular subtypes in solid cancers: successes and failures.

Auteurs : Assi R, Kotecki N, Awada A
Année : 2020
Journal : Curr Opin Oncol
Volume : 32
Pages : 488-493

A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor-Positive Breast Cancer.

Auteurs : Tolaney SM, Sahebjam S, Le Rhun E, Bachelot T, Kabos P, Awada A, Yardley D, Chan A, Conte P, Diéras V, Lin NU, Bear M, Chapman SC, Yang Z, Chen Y, Anders CK
Année : 2020
Journal : Clin Cancer Res
Volume : 26
Pages : 5310-5319

[Tolerablity of everolimus in clinical practice: a retrospective study].

Auteurs : Afani L, Belbaraka R, Awada A
Année : 2020
Journal : Pan Afr Med J
Volume : 36
Pages : 26

Bintrafusp alfa, a bifunctional fusion protein targeting TGF-ß and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohort.

Auteurs : Cho BC, Daste A, Ravaud A, Salas S, Isambert N, McClay E, Awada A, Borel C, Ojalvo LS, Helwig C, Rolfe PA, Gulley JL, Penel N
Année : 2020
Journal : J Immunother Cancer
Volume : 8

MOMENTUM: A Phase I Trial Investigating 2 Schedules of Capecitabine With Aflibercept in Patients With Gastrointestinal and Breast Cancer.

Auteurs : Camera S, Deleporte A, Bregni G, Trevisi E, Pretta A, Telli TA, Polastro L, Gombos A, Kayumba A, Ameye L, Piccart-Gebhart M, Awada A, Sclafani F, Hendlisz A
Année : 2020
Journal : Clin Colorectal Cancer
Volume : 19
Pages : 311-318.e1

Computed tomography-based analyses of baseline body composition parameters and changes in breast cancer patients under treatment with CDK 4/6 inhibitors.

Auteurs : Franzoi MA, Vandeputte C, Eiger D, Caparica R, Brandão M, de Angelis C, Hendlisz A, Awada A, Piccart-Gebhart M, de Azambuja E
Année : 2020
Journal : Breast Cancer Res Treat
Volume : 181
Pages : 199-209

Prognostic and Predictive Impact of Beta-2 Adrenergic Receptor Expression in HER2-Positive Breast Cancer.

Auteurs : Caparica R, Richard F, Brandão M, Awada A, Sotiriou C, de Azambuja E
Année : 2020
Journal : Clin Breast Cancer
Volume : 20
Pages : 262-273.e7

Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial.

Auteurs : Trigo J, Subbiah V, Besse B, Moreno V, López R, Sala MA, Peters S, Ponce S, Fernández C, Alfaro V, Gómez J, Kahatt C, Zeaiter A, Zaman K, Boni V, Arrondeau J, Martínez M, Delord JP, Awada A, Kristeleit R, Olmedo ME, Wannesson L, Valdivia J, Rubio MJ, Anton A, Sarantopoulos J, Chawla SP, Mosquera-Martinez J, DArcangelo M, Santoro A, Villalobos VM, Sands J, Paz-Ares L
Année : 2020
Journal : Lancet Oncol
Volume : 21
Pages : 645-654

Kinome Profiling to Predict Sensitivity to MAPK Inhibition in Melanoma and to Provide New Insights into Intrinsic and Acquired Mechanism of Resistance.

Auteurs : Krayem M, Aftimos P, Najem A, van den Hooven T, van den Berg A, Hovestad-Bijl L, de Wijn R, Hilhorst R, Ruijtenbeek R, Sabbah M, Kerger J, Awada A, Journe F, Ghanem G
Année : 2020
Journal : Cancers (Basel)
Volume : 12

Reimagining Global Oncology Clinical Trials for the Postpandemic Era: A Call to Arms.

Auteurs : Saini KS, de Las Heras B, Plummer R, Moreno V, Romano M, de Castro J, Aftimos P, Fredriksson J, Bhattacharyya GS, Olivo MS, Schiavon G, Punie K, Garcia-Foncillas J, Rogata E, Pfeiffer R, Orbegoso C, Morrison K, Curigliano G, Chin L, Saini ML, Rekdal Ø, Anderson S, Cortes J, Leone M, Dancey J, Twelves C, Awada A
Année : 2020
Journal : JCO Glob Oncol
Volume : 6
Pages : 1357-1362

159P The clinical landscape of central nervous system (CNS) involvement in metastatic triple-negative breast cancer (TNBC) patients (pts)

Auteurs : Eiger D, de Azambuja E, Moreau M, Bondele J, Sotiriou C, Franzoi MA, Brandão M, Rediti M, Wang X, Awada A, Kotecki N
Année : 2020
Journal : Ann Oncol
Volume : 31(2)
Pages : S73-S74

Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment.

Auteurs : Subbiah V, Paz-Ares L, Besse B, Moreno V, Peters S, Sala MA, López-Vilariño JA, Fernández C, Kahatt C, Alfaro V, Siguero M, Zeaiter A, Zaman K, López R, Ponce S, Boni V, Arrondeau J, Delord JP, Martínez M, Wannesson L, Antón A, Valdivia J, Awada A, Kristeleit R, Olmedo ME, Rubio MJ, Sarantopoulos J, Chawla SP, Mosquera-Martinez J, D Arcangelo M, Santoro A, Villalobos VM, Sands J, Trigo J
Année : 2020
Journal : Lung Cancer
Volume : 150
Pages : 90-96

Erratum: Krayem, M., et al. Kinome Profiling to Predict Sensitivity to MAPK Inhibition in Melanoma and to Provide New Insights into Intrinsic and Acquired Mechanism of Resistance Short Title: Sensitivity Prediction to MAPK Inhibitors in Melanoma. <i>

Auteurs : Krayem M, Aftimos P, Najem A, Hooven TVD, Berg AVD, Hovestad-Bijl L, Wijn R, Hilhorst R, Ruijtenbeek R, Sabbah M, Kerger J, Awada A, Journe F, Ghanem G
Année : 2020
Journal : Cancers (Basel)
Volume : 12

Diagnosis, pathophysiology, and treatment of SIRT-induced gastroduodenal ulcers: A systematic literature review.

Auteurs : Laila B, Vinciane L, Michael V, Patrick F, Awada A, Maria GG, Liberale G
Année : 2020
Journal : Surg Oncol
Volume : 35
Pages : 520-526

Oncological care organisation during COVID-19 outbreak.

Auteurs : Onesti CE, Rugo HS, Generali D, Peeters M, Zaman K, Wildiers H, Harbeck N, Martin M, Cristofanilli M, Cortes J, Tjan-Heijnen V, Hurvitz SA, Berchem G, Tagliamento M, Campone M, Bartsch R, De Placido S, Puglisi F, Rottey S, Müller V, Ruhstaller T, Machiels JP, Conte P, Awada A, Jerusalem G
Année : 2020
Journal : ESMO Open
Volume : 5

A Randomized Placebo Controlled Phase II Trial Evaluating Exemestane with or without Enzalutamide in Patients with Hormone Receptor-Positive Breast Cancer.

Auteurs : Krop I, Abramson V, Colleoni M, Traina T, Holmes F, Garcia-Estevez L, Hart L, Awada A, Zamagni C, Morris PG, Schwartzberg L, Chan S, Gucalp A, Biganzoli L, Steinberg J, Sica L, Trudeau M, Markova D, Tarazi J, Zhu Z, OBrien T, Kelly CM, Winer E, Yardley DA
Année : 2020
Journal : Clin Cancer Res
Volume : 26
Pages : 6149-6157

Oncology care: keep it going, Learn – Improve – Act (white paper BE, IPSEN, ALL-BE-000191- Oct 2020)

Auteurs : Awada A, Ameye F, Bangma CH, Bloemendal H, van Damme J, Gennigens C, de Herder W, Lybaert W, De Meerleer G, Peeters M, Romijn JA, Rottey S, Sedelaar JP, Seront E, Stouthard JM, Suelmann B, Tuytten T, Valk G, De Vries S, Willemse P
Année : 2020
Journal : IPSEN
Volume : -
Pages : -